[Involving patients in the evaluation of health technologies at the French National Authority for Health (HAS)].
The French National Authority for Health (HAS) wanted to establish a review about the first months of its new patient involvement process dedicated to drug and medical device evaluation (which began in November 2016). This process relies on written submissions from patient organizations (POs). Different sources of information were used: data monitoring, comparison with other contribution processes in HAS, sharing of practices with other Health Technology Assessment (HTA) bodies, feedback discussions with POs, pharmaceuticals firms, and evaluators (internal reviewers and members of Appraisal Committees). There were contributions for 25 drugs among 75 opened to contribution during the first six months. The HAS Board defined three adjustments in September 2017 to improve the procedure: increasing the time for POs to contribute, publishing the contributions on the HAS website, improvement of the presentation of the submission to the committee. Some further necessary reflections were identified such as the information available to POs to elaborate their submission, or the exact nature of intellectual uptake of the contribution during the different stages of assessment/appraisal elaboration. The different methods proved to be complementary and helped to define adjustments and clarify some future stakes for this new procedure. Data on this kind of process must be routinely collected. Comparisons with other involvement processes and discussions with stakeholders are rather used in dedicated studies or improvements projects.